BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 1560435)

  • 1. Antimycobacterial activity of a series of pyrazinoic acid esters.
    Cynamon MH; Klemens SP; Chou TS; Gimi RH; Welch JT
    J Med Chem; 1992 Apr; 35(7):1212-5. PubMed ID: 1560435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative structure-activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters.
    Bergmann KE; Cynamon MH; Welch JT
    J Med Chem; 1996 Aug; 39(17):3394-400. PubMed ID: 8765523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Esters of Pyrazinoic Acid Are Active against Pyrazinamide-Resistant Strains of Mycobacterium tuberculosis and Other Naturally Resistant Mycobacteria In Vitro and Ex Vivo within Macrophages.
    Pires D; Valente E; Simões MF; Carmo N; Testa B; Constantino L; Anes E
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7693-9. PubMed ID: 26438493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity.
    Cynamon MH; Gimi R; Gyenes F; Sharpe CA; Bergmann KE; Han HJ; Gregor LB; Rapolu R; Luciano G; Welch JT
    J Med Chem; 1995 Sep; 38(20):3902-7. PubMed ID: 7562923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimycobacterial activity of pyrazinoate prodrugs in replicating and non-replicating Mycobacterium tuberculosis.
    Segretti ND; Simões CK; Corrêa MF; Felli VMA; Miyata M; Cho SH; Franzblau SG; Fernandes JPDS
    Tuberculosis (Edinb); 2016 Jul; 99():11-16. PubMed ID: 27449999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro antimycobacterial activities of pyrazinamide analogs.
    Yamamoto S; Toida I; Watanabe N; Ura T
    Antimicrob Agents Chemother; 1995 Sep; 39(9):2088-91. PubMed ID: 8540721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide.
    Speirs RJ; Welch JT; Cynamon MH
    Antimicrob Agents Chemother; 1995 Jun; 39(6):1269-71. PubMed ID: 7574514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. QSAR modeling of a set of pyrazinoate esters as antituberculosis prodrugs.
    Fernandes JP; Pasqualoto KF; Felli VM; Ferreira EI; Brandt CA
    Arch Pharm (Weinheim); 2010 Feb; 343(2):91-7. PubMed ID: 20099263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro antimycobacterial activity of 5-chloropyrazinamide.
    Cynamon MH; Speirs RJ; Welch JT
    Antimicrob Agents Chemother; 1998 Feb; 42(2):462-3. PubMed ID: 9527809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and antimycobacterial activity of pyrazine and quinoxaline derivatives.
    Seitz LE; Suling WJ; Reynolds RC
    J Med Chem; 2002 Dec; 45(25):5604-6. PubMed ID: 12459027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron enhances the antituberculous activity of pyrazinamide.
    Somoskovi A; Wade MM; Sun Z; Zhang Y
    J Antimicrob Chemother; 2004 Feb; 53(2):192-6. PubMed ID: 14729751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid.
    Zhang Y; Wade MM; Scorpio A; Zhang H; Sun Z
    J Antimicrob Chemother; 2003 Nov; 52(5):790-5. PubMed ID: 14563891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipophilic pyrazinoic acid amide and ester prodrugs stability, activation and activity against M. tuberculosis.
    Simões MF; Valente E; Gómez MJ; Anes E; Constantino L
    Eur J Pharm Sci; 2009 Jun; 37(3-4):257-63. PubMed ID: 19491013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and antimycobacterial evaluation of N-substituted 3-aminopyrazine-2,5-dicarbonitriles.
    Zitko J; Jampílek J; Dobrovolný L; Svobodová M; Kuneš J; Doležal M
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1598-601. PubMed ID: 22281187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and antimycobacterial evaluation of pyrazinamide derivatives with benzylamino substitution.
    Zitko J; Paterová P; Kubíček V; Mandíková J; Trejtnar F; Kuneš J; Doležal M
    Bioorg Med Chem Lett; 2013 Jan; 23(2):476-9. PubMed ID: 23237840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli.
    Zimhony O; Vilchèze C; Arai M; Welch JT; Jacobs WR
    Antimicrob Agents Chemother; 2007 Feb; 51(2):752-4. PubMed ID: 17101678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimycobacterial activity of basic ethyl esters of alkoxy-substituted phenylcarbamic acids.
    Waisser K; Drazková K; Cizmárik J; Kaustová J
    Folia Microbiol (Praha); 2003; 48(1):45-50. PubMed ID: 12744075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyrazinamide and pyrazinoic acid activity against tubercle bacilli in cultured human macrophages and in the BACTEC system.
    Salfinger M; Crowle AJ; Reller LB
    J Infect Dis; 1990 Jul; 162(1):201-7. PubMed ID: 2113074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Acid-Base Equilibrium of Pyrazinoic Acid Drives the pH Dependence of Pyrazinamide-Induced
    Fontes FL; Peters BJ; Crans DC; Crick DC
    ACS Infect Dis; 2020 Nov; 6(11):3004-3014. PubMed ID: 33078607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, antimycobacterial activity and in vitro cytotoxicity of 5-chloro-N-phenylpyrazine-2-carboxamides.
    Zitko J; Servusová B; Paterová P; Mandíková J; Kubíček V; Kučera R; Hrabcová V; Kuneš J; Soukup O; Doležal M
    Molecules; 2013 Dec; 18(12):14807-25. PubMed ID: 24317522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.